Surrozen Inc. (SRZN)
SRZN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1824893/000119312526119818/0001193125-26-119818-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | SRZN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001824893 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.5M |
| Net income | -$242.0M |
| Operating income | -$42.1M |
| Net margin | -6960.8% |
| Operating margin | -1210.6% |
| Revenue growth | -67.4% |
| Cash | $89.2M |
| Total assets | $98.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 177.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $100.4M cash; operating cash flow -$7.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 19,061,662 (2026-11-05); 8,571,421 a year earlier; 30,575,047 three years earlier. 3y figure adjusted for split (1-for-15 overall). | Cover page 2026-11-05 |
| Reverse splits, 3 years | 1; latest 1-for-15 on 2023-12-14 | Source 2023-12-14 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-03-30 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2026-08-07 |
| Auditor | Ernst & Young LLP, San Francisco, California, United States | PCAOB Form AP 2026-04-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $9.4M, sold $3.8M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$129.7M | -$4.8M | $100.4M | No debt tags | $10.5M | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $5.0M | $50.2M | -$7.4M | $102.0M | No debt tags | $11.5M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $5.0M | -$127.5M | -$12.5M | $106.9M | No debt tags | $7.5M | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $528K | -$183.2M | -$5.8M | $89.2M | No debt tags | $3.5M | 10-K 2026-03-23 |
| Q3 2025 2025-09-30 | $983K | -$71.6M | -$9.0M | $81.3M | No debt tags | $3.6M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $983K | $39.7M | -$6.1M | $90.4M | No debt tags | $12.6M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $983K | -$27.0M | -$9.3M | $101.6M | No debt tags | $11.6M | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $655K | -$28.0M | $3.5M | $34.6M | No debt tags | $10.7M | 10-K 2026-03-23 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-11-16 |
| Latest annual report | 10-K | 2026-03-23 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-04-01 |
Source: SEC EDGAR submissions feed, 510 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.0% |
| 1 month | +34.5% |
| 3 months | +33.2% |
| Year to date | +39.9% |
| 1 year | +160.8% |
| From 52-week high | -7.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CGEM | Cullinan Therapeutics Inc. | $9.50 | -7.59% | $616.7M |
| FDMT | 4D Molecular Therapeutics Inc. | $11.29 | -7.69% | $636.5M |
| BBTX | Bambusa Therapeutics Inc. | $15.98 | -0.68% | $645.4M |
| DBVT | DBV Technologies S.A. | $10.27 | -6.76% | $645.8M |
| ATTO | Attovia Therapeutics Inc. | $14.72 | -2.68% | $673.1M |
| SANA | Sana Biotechnology Inc. | $1.88 | -6.93% | $563.3M |
| IAM | Iambic Therapeutics Inc. | $11.85 | -9.54% | $561.7M |
| DNA | Ginkgo Bioworks Holdings Inc. | $8.50 | -11.55% | $551.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier